CBLL vs NEOG vs BFLY Stock Comparison

Ceribell, Neogen and Butterfly Network Prices as of Oct 23, 2026 Peers: Industry group
CBLL Ceribell, Inc.
$27.13 +14.9% 1M +109.7% 1Y
Market cap
$1.03B
P/E
–
Revenue (TTM)
$101.96M
Div. yield
–
Diagnostic Equipment Healthcare
3 wins
NEOG Neogen Corp
$12.19 -10.2% 1M +100.8% 1Y
Market cap
$2.66B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
3 wins
BFLY Butterfly Network, Inc.
$6.76 -26.5% 1M +204.5% 1Y
Market cap
$1.74B
P/E
–
Revenue (TTM)
$112.15M
Div. yield
–
Diagnostic Equipment Healthcare
2 wins

Head to Head

8 decided of 12

Neogen leads on 3 of the 12 questions below (Neogen 3, Ceribell 3, Butterfly Network 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCBLLNEOGBFLYLeader
Larger companyMarket capitalisation $1.03B $2.66B $1.74B NEOG
Cheaper on earningsLower P/E, profitable companies only -15.6x -47.4x -23.3x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 39.3x — –
Faster revenue growthRevenue growth, trailing twelve months +31.7% -0.3% +28.1% CBLL
More profitableNet margin, trailing twelve months -64.7% -6.3% -66.7% NEOG
Better return on capitalReturn on invested capital — -0.2% — –
Less leveragedLower net debt / EBITDA 1.6x 5.4x — CBLL
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +109.7% +100.8% +204.5% BFLY
Better 5-year returnAnnualised price return, 5 years — -21.6%/yr -8.2%/yr BFLY
Less volatileAnnualised volatility, 1 year 52.1% 55.6% 114.4% CBLL
Higher overall scoreMean of the five percentile scores vs peers 38/100 57/100 45/100 NEOG

Percentile Scorecard

CBLLNEOGBFLY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCBLLNEOGBFLY
Valuation 22 #179 of 228 72 #65 of 228 28 #164 of 228
Growth 20 #177 of 222 48 #115 of 222 68 #72 of 222
Profitability 36 #134 of 210 61 #83 of 210 31 #145 of 210
Financial Health 81 #46 of 241 47 #129 of 241 61 #95 of 241
Shareholder Returns 30 #97 of 138 58 #59 of 138 35 #90 of 138
Overall 38 57 45
  • CBLL ranked among 248 companies in Medical Devices and Diagnostics
  • NEOG ranked among 248 companies in Medical Devices and Diagnostics
  • BFLY ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCBLLNEOGBFLYSPY
1 month +14.9%-10.2%-26.5% -1.0%
3 months +60.4%+29.7%+3.0% +2.9%
6 months +28.1%+27.8%+26.8% +6.4%
Year to date +23.7%+74.4%+77.9% +11.4%
1 year +109.7%+100.8%+204.5% +13.1%
3 years —-19.8%+611.6% +79.4%
3 years, per year —-7.1%+92.4% +21.5%
5 years —-70.3%-34.7% +67.7%
5 years, per year —-21.6%-8.2% +10.9%
10 years —-37.6%— +255.2%
10 years, per year —-4.6%— +13.5%

Risk

MeasureCBLLNEOGBFLYSPY
Volatility, 1Y 52.1%55.6%114.4% 12.7%
Downside volatility, 1Y 49.5%46.5%91.7% 12.7%
Beta vs S&P 500, 1Y 1.201.442.94 1.00
Return / volatility, 1Y 2.101.811.79 1.03
Max drawdown, 5Y -63.9%-90.6%-93.5% -25.4%
From 52-week high -2.0%-12.8%-32.0% -2.5%
52-week high $27.68$13.98$9.94 $779.14
52-week low $10.92$5.41$1.97 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCBLLNEOGBFLY
P/E now vs peer median -15.6xmedian 30.7x -47.4xmedian 30.7x -23.7xmedian 30.7x
P/S now vs peer median 10.2xmedian 3.0x 3.0xmedian 3.0x 14.3xmedian 3.0x
EV/EBITDA now vs peer median -13.6xmedian 17.7x 29.4xmedian 17.7x -20.5xmedian 17.7x
P/FCF now vs peer median -19.0xmedian 23.7x 53.4xmedian 23.7x -57.4xmedian 23.7x
P/B now vs peer median 8.1xmedian 2.4x 1.3xmedian 2.4x 8.5xmedian 2.4x
PEG now vs peer median —median 0.96 1.69median 0.96 -0.88median 0.96

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCBLLNEOGBFLY
Revenue $101.96M $883.99M $112.15M
Gross profit $90.65M $418.98M $59.04M
Operating income -$69.97M -$7.38M -$79.38M
Net income -$66.00M -$56.10M -$74.85M
Free cash flow -$54.72M $49.80M -$28.04M
R&D $22.95M $19.76M $38.10M
EPS (diluted) $-1.74 $-0.26 $-0.29
Cash & equivalents $32.66M $172.00M $124.66M
Total debt $79.45M $3.15B –
Shares (diluted) 38.03M 218.10M 262.10M
Enterprise value $429.38M $2.00B $1.19B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCBLLNEOGBFLY
P/E -15.6x -47.4x -23.7x
P/FCF -19.0x 53.4x -57.4x
P/Operating cash flow -19.2x 31.2x -67.0x
P/S 10.2x 3.0x 14.3x
P/B 8.1x 1.3x 8.5x
P/Tangible book 8.1x 3.4x 8.8x
EV/EBITDA -13.6x 29.4x -20.5x
EV/EBIT -13.3x -442.4x -18.7x
EV/Revenue 9.1x 3.7x 13.2x
EV/FCF -17.0x 65.5x -52.9x
EV/Operating cash flow -17.2x 38.3x -61.8x
PEG (3Y EPS CAGR) – 1.69 -0.88

Growth

14 metrics
MetricCBLLNEOGBFLY
Revenue growth (1Y) 31.7% -0.3% 28.1%
Revenue CAGR (3Y) – -1.3% 15.6%
Gross profit growth (1Y) 33.4% 1.8% 8.8%
Gross profit CAGR (3Y) – -3.1% 13.3%
Operating income growth (1Y) -34.6% 99.3% -14.8%
Operating income CAGR (3Y) – -29.0% 21.1%
Net income growth (1Y) -33.6% 94.6% -19.1%
Net income CAGR (3Y) – -28.3% 20.8%
EPS growth (1Y) -27.5% 94.6% -12.9%
EPS CAGR (3Y) – -28.0% 27.0%
Operating cash flow growth (1Y) -44.3% -1.9% 19.6%
Operating cash flow CAGR (3Y) – 2.9% 44.5%
Free cash flow growth (1Y) -41.8% 1,631% 12.2%
Free cash flow CAGR (3Y) – 126.1% 42.8%

Profitability

14 metrics
MetricCBLLNEOGBFLY
Gross margin 88.9% 47.4% 52.6%
EBITDA margin -67.1% 12.5% -64.4%
Operating margin -68.6% -0.8% -70.8%
Pretax margin -64.7% -7.7% -66.7%
Net margin -64.7% -6.3% -66.7%
FCF margin -53.7% 5.6% -25.0%
Operating cash flow margin -53.0% 9.6% -21.4%
Return on equity -49.0% -2.7% -39.3%
Return on assets -38.3% -1.7% -26.3%
Return on invested capital – -0.2% –
Return on capital employed -45.1% -0.2% -35.1%
Asset turnover 0.6x 0.3x 0.4x
Cash conversion (OCF / net income) 0.8x -1.5x 0.3x
Stock comp / revenue 16.1% 1.3% 21.3%

Financial Health

11 metrics
MetricCBLLNEOGBFLY
Debt / assets 12.0% 23.4% –
Debt / equity 0.2x 0.4x –
Net debt / EBITDA 1.6x 5.4x –
Debt / FCF -0.4x 15.5x –
Liabilities / assets 22.9% 36.8% 33.1%
Equity / assets 77.1% 63.2% 66.9%
Interest coverage -38.6x – -59.4x
Current ratio 9.2x 3.9x 4.1x
Quick ratio 8.6x 2.1x 2.7x
Cash ratio 7.5x 1.2x 2.1x
Altman Z-score 14.41 1.49 6.07

Shareholder Returns

7 metrics
MetricCBLLNEOGBFLY
Dividend yield – – –
Net buyback yield -0.6% -0.1% -0.5%
Shareholder yield -0.6% -0.1% -0.5%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCBLLNEOGBFLY
Forward P/E – 39.3xFY2026 –
EPS, next fiscal year $-1.86FY2026 $0.31FY2026 $-0.10FY2026
EPS growth, next FY – -3.1%FY2026 –
EPS growth, the year after – +25.8% –
Revenue, next fiscal year $118.32MFY2026 $845.87MFY2026 $114.50MFY2026
Revenue growth, next FY +32.9%FY2026 -2.8%FY2026 +17.3%FY2026
Revenue growth, the year after +21.1% +1.0% +26.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCBLLNEOGBFLY
Held by institutions 79.9% 100.0% 59.9%
Institutions holding 124 315 245
Change in shares held, QoQ +2.2% +1.6% +13.9%
Institutions buying 74 151 143
Institutions selling 36 106 59
Buyers to sellers 2.06 1.42 2.42

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CBLLNEOGBFLY
CBLL 1.00 0.25 0.37
NEOG 0.25 1.00 0.25
BFLY 0.37 0.25 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CBLL, NEOG and BFLY?

Neogen (NEOG) is the largest by market capitalisation: Ceribell (CBLL) $1.03B, Neogen (NEOG) $2.66B, Butterfly Network (BFLY) $1.74B.

Which company is growing faster?

Ceribell (CBLL) grew revenue fastest over the trailing twelve months: Ceribell (CBLL) +31.7%, Neogen (NEOG) -0.3%, Butterfly Network (BFLY) +28.1%.

Which company is more profitable?

Neogen (NEOG) has the highest net margin (Ceribell (CBLL) -64.7%, Neogen (NEOG) -6.3%, Butterfly Network (BFLY) -66.7%).

Which stock has performed better?

Over the past year Butterfly Network (BFLY) returned the most: Ceribell (CBLL) +109.7%, Neogen (NEOG) +100.8%, Butterfly Network (BFLY) +204.5%. Over five years, Butterfly Network (BFLY) compounded fastest (Neogen (NEOG) -21.6%/yr, Butterfly Network (BFLY) -8.2%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Ceribell (CBLL) has been the steadiest (Ceribell (CBLL) 52.1%, Neogen (NEOG) 55.6%, Butterfly Network (BFLY) 114.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CBLL, NEOG and BFLY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Neogen (NEOG) leads on 3. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.